HomeRobert A. Hauser, M.D., M.B.A.
| Address: | 5 Tampa General Circle, Suite 410 Tampa, FL 33606 |
| USF Mail stop: | HMT 410 |
| Phone: |
For Assitant Alyssa: For patients: |
| Fax: | (813) 844-4456 |
| Email: | rhauser@health.usf.edu |
| Medical School: | Temple University School of Medicine |
| Residency: | Eastern Virginia Graduate School of Medicine (Neurology) |
| Fellowship: | University of South Florida, College of Medicine under C.W. Olanow, M.D. (Movement Disorders) |
| Clinical Interests: |
Dr. Hauser provides expert evaluation and care for individuals with Parkinson's disease and other movement disorders including Parkinsonism, tremor, chorea, dystonia, and restless legs syndrome. Patients may be offered the opportunity to participate in clinical trials and information gained from these trials is utilized to provide cutting edge therapy for patients. Dr. Hauser is an authority on botulinum toxin injections for the treatment of movement disorders, having performed such injections for over 20 years. Botulinum toxin injections are provided for a variety of disorders including cervical dystonia, blepharospasm, hemifacial spasm, and other involuntary movements. |
| Research Interests: |
Dr. Hauser's research focuses on the development of new treatments for Parkinson's disease and other movement disorders including essential tremor, cervical dystonia, blepharospasm, hemifacial spasm, Huntington's disease, and restless legs syndrome. His expertise includes clinical trial design and execution. Dr. Hauser is the lead investigator for several national and international clinical trials and he serves on steering committees for multiple drug development programs and individual clinical trials. Developing medications to slow or stop the progression of neurodegenerative disorders is a top priority. |
| Board Certification(s) |
|
| Specialties: |
|
| Additional Information: |
Dr. Hauser has authored or co-authored more than 150 peer-reviewed publications and has lectured frequently at scientific meetings around the world. He is Past Chairman of the Interventional Neurology Section of the American Academy of Neurology, has served on the executive committee of the Parkinson Study Group, and is a member of the steering committee for the NIH (National Institutes of Health) Neuroprotective Exploratory Trials in Parkinson's Disease Program (NET-PD). Dr. Hauser serves as an international leader in the advancement of disease management and utilizes this knowledge to provide the highest quality care to patients, and to educate students, residents, and other physicians. |
Hauser RA, Freeman TB, Snow BJ, Nauert M, Gauger L, Kordower JH, Olanow CW. Long-term evaluation of bilateral fetal nigral transplantation in Parkinson's disease. Archives of Neurology 1999;56:179-87.
Hauser RA, Furtado S, Cimino CR, Delgado H, Eichler S, Schwartz S, Scott D, Nauert GM, Soety E, Sossi V, Holt A, Sanberg PR, Stoessl AJ, Freeman TB. Bilateral human fetal striatal transplantation in Huntington's disease. Neurology 2002;58:687-95.
Hauser RA, Hubble JP, Truong DD, Istradefylline US-001 Study Group. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.
Hauser RA, Lyons K. Future treatments for Parkinson's disease. Neurologic Clinics 2004;22(3 Suppl):S149-66.
Hauser RA, Zesiewicz T. Clinical trials aimed at detecting neuroprotection in Parkinson's disease. Neurology 2006;66(10 Suppl 4):S58-S68.
Hauser RA, McDermott MP, Messing S, and the Parkinson Study Group. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson's disease. Archives of Neurology 2006;63:1756-1760.
Hauser RA, Zesiewicz TA. Advances in the pharmacologic management of early Parkinson disease. The Neurologist 2007;13126-32.
Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa. Movement Disorders 2007;22:2409-17.
Hauser RA, Panisset M, Abbruzzese G, Mancione L, Dronamraju N, Kakarieka A, on behalf of the FIRST-STEP Study Group. Double-blind trial of levodopa/carbidopa/entacapone versus levodopa/carbidopa in early PD. Movement Disorders, In Press.
Hauser RA, MD, Lew MF, Hurtig HI, Ondo WG, Wojcieszek J, Fitzer-Attas CJ, on behalf of the TEMPO Open-label Study Group. Long-term Outcome of Early Versus Delayed Rasagiline Treatment in Early Parkinson's Disease. Movement Disorders, In Press.